Ravi Bhatia

What is he best known for?

The fields of study he is best known for:

• Gene
• Cancer
• Internal medicine

Ravi Bhatia mainly focuses on Cancer research, Chronic myelogenous leukemia, Leukemia, Stem cell and Imatinib mesylate. The various areas that Ravi Bhatia examines in his Cancer research study include Haematopoiesis, Progenitor cell, Tyrosine kinase, Kinase activity and Bone marrow. His Chronic myelogenous leukemia research is multidisciplinary, incorporating elements of K562 cells and Philadelphia chromosome.

His research integrates issues of Myeloid, Myeloid leukemia and Transplantation in his study of Leukemia. He does research in Stem cell, focusing on Cancer stem cell specifically. His Imatinib mesylate study integrates concerns from other disciplines, such as breakpoint cluster region and ABL.

His most cited work include:

• Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is effective in patients with Philadelphia chromosome–positive chronic myelogenous leukemia in chronic phase following imatinib resistance and intolerance (638 citations)
• Persistence of malignant hematopoietic progenitors in chronic myelogenous leukemia patients in complete cytogenetic remission following imatinib mesylate treatment. (492 citations)
• miR-328 Functions as an RNA Decoy to Modulate hnRNP E2 Regulation of mRNA Translation in Leukemic Blasts (422 citations)

What are the main themes of his work throughout his whole career to date?

His primary areas of study are Cancer research, Stem cell, Progenitor cell, Immunology and Leukemia. The concepts of his Cancer research study are interwoven with issues in Chronic myelogenous leukemia and Tyrosine kinase, ABL. His work investigates the relationship between Chronic myelogenous leukemia and topics such as Integrin that intersect with problems in Cell adhesion and Cell adhesion molecule.

His Stem cell study combines topics in areas such as Myeloid and Bone marrow. His biological study spans a wide range of topics, including Cancer cell, Molecular biology, Apoptosis and CD38. His Leukemia study is related to the wider topic of Internal medicine.

He most often published in these fields:

• Cancer research (47.45%)
• Stem cell (34.18%)
• Progenitor cell (32.14%)

What were the highlights of his more recent work (between 2015-2021)?

• Cancer research (47.45%)
• Stem cell (34.18%)
• Internal medicine (21.17%)

In recent papers he was focusing on the following fields of study:

Ravi Bhatia mostly deals with Cancer research, Stem cell, Internal medicine, Leukemia and Myeloid leukemia. His research integrates issues of Cell growth, Progenitor cell, Tyrosine kinase, ABL and Chronic myelogenous leukemia in his study of Cancer research. His research in Stem cell intersects with topics in Immunology and Bone marrow.

His work in Internal medicine tackles topics such as Oncology which are related to areas like Philadelphia chromosome, Discontinuation, Polycythemia vera, Risk stratification and Essential thrombocythemia. His study in the field of Myelogenous also crosses realms of PARP1. His Myeloid leukemia study combines topics from a wide range of disciplines, such as Hematopoietic stem cell transplantation, DNA methylation, CXCR4, CD33 and Drug resistance.

Between 2015 and 2021, his most popular works were:

• High Frequency and Poor Outcome of Philadelphia Chromosome-Like Acute Lymphoblastic Leukemia in Adults. (172 citations)
• Clonal Hematopoiesis Associated With Adverse Outcomes After Autologous Stem-Cell Transplantation for Lymphoma (162 citations)
• Chronic myeloid leukemia, version 1.2019 (137 citations)

In his most recent research, the most cited papers focused on:

• Gene
• Cancer
• Internal medicine

Leukemia, Cancer research, Stem cell, Myeloid leukemia and Internal medicine are his primary areas of study. His study with Leukemia involves better knowledge in Immunology. The Cancer research study combines topics in areas such as Haematopoiesis, Bone marrow, Tyrosine-kinase inhibitor and DNA repair.

His study in Stem cell is interdisciplinary in nature, drawing from both Chronic myelogenous leukemia and Tyrosine kinase, Nilotinib. His Internal medicine research incorporates themes from Philadelphia chromosome and Oncology. Ravi Bhatia studied Hematopoietic stem cell and breakpoint cluster region that intersect with ABL.